Clinical Trial Update: VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for VMD-928 as a monotherapy and in combination with pembrolizumab to treat TrkA overexpression-driven solid tumors or lymphoma. The study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenoid Cystic Carcinoma
• Esophageal Cancer
• Head and Neck Cancer
• Mesothelioma
• Non-small Cell Lung Cancer
• Pancreatic Cancer
• Salivary Gland Carcinoma
• Small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• VMD-928

Snippet

Sponsor: VM Oncology, LLC | Conditions: Head and Neck Carcinoma, Adenoid Cystic Carcinoma | Phase 1, Phase 2 | Status: RECRUITING